Loading…
Loading…
ZLDAF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZLDAF and 80,000+ other tickers.
See exactly how ZLDAF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZLDAF and 80,000+ other tickers.
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC…
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Zelira Therapeutics (OTCMKTS:ZLDAF - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings This table compares Hyperion DeFi
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has secured a major funding milestone after its HOPE® 1 special purpose vehicle (SPV) signed definitive...
Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report) were up 13.9% during mid-day trading on Monday. The stock traded as high as $0.2660 and last traded at $0.2660. Approximately 171 shares were traded during trading, a decline of 82% from the average daily volume of 973 shares. The stock had previously closed
Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $0.2056 and last traded at $0.2056. Approximately 228 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 936 shares. The stock had previously closed
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is well placed to generate further growth in cash flow and revenue via its diversified income streams, with a suite of new products launched in H1 FY2022. The company generated quarterly cash receipts of $0.341 million in Q2 FY2022 underpinned by sales of SprinjeneCBD and consulting payments, relatively stable to Q1 FY2022's $0.362 million.